PSMA–DA1
2703051-77-6
|
PSMA-ALB-56
2306049-48-7
|
PSMA; peptide 288-297
345634-90-4
|
PSMA-ligand-1
1610413-97-2
|
PSMA I&T
2192281-54-0
|
PSMA I&S
2639475-07-1
|
PSMA-617
1702967-37-0
|
Osimertinib analogue
2050521-74-7
|
EZETIMIBE ANALOGUE
194423-53-5
|
4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
1158522-08-7
|
1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
940364-43-2
|
2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
134104-43-1
|
1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
131615-57-1
|
rac-2-{[(3R,4R)-1-acetyl-4-hydroxypyrrolidin-3-yl](methyl)amino}acetic acid
2679949-23-4
|
benzyl N-[(5-bromopyrimidin-2-yl)methyl]carbamate
2680662-76-2
|
(4-Methyl-tetrahydro-furan-2-yl)-methanol
6906-52-1
|
N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
930439-75-1
|
4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
1018584-77-4
|
tert-Butyl-DL-alanine
1375289-11-4
|
